The global Pemphigus Vulgaris market is expected to reach USD 677.32 million by 2030 from USD 362.59 million in 2022, growing at a CAGR of 8.2% during the forecast period of 2023 to 2030.
Market Segmentation:
Global Pemphigus Vulgaris Market, By Diagnosis and Treatment (Diagnosis, Treatment), Population Type (Pediatric, Adults, and Geriatric), End User (Hospitals, Specialty Clinics, Research Institutes, and Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy) - Industry Trends and Forecast to 2030.
Overview of Global Pemphigus Vulgaris Market Dynamics :
- Driver
- Rise in patients with rare diseases such as pemphigus vulgaris
- Restraint
- High cost of treatment
- Opportunity
- Rising healthcare facilities in the developing and underdeveloped countries
Market Players
The key market players operating in the market are:
- F-Hoffmann La Roche Ltd.
- Sanofi
- Regeneron Pharmaceuticals Inc.
- Fresenius Kabi AG
- Boehringer Ingelheim International GmbH
- Johnson & Johnson Services, Inc.
- RAKSHIT DRUGS PVT. LTD
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Celltrion Healthcare Co., Ltd.
- AbbVie Inc.
- Novartis AG
- Amgen Inc.
- Merck & Co., Inc.
- AstraZeneca
- Teva Pharmaceutical Industries Ltd
- Lilly
- Zydus Group
- GSK plc.
TABLE OF CONTENTS
1 INTRODUCTION 32
- 1.1 OBJECTIVES OF THE STUDY 32
- 1.2 MARKET DEFINITION 32
- 1.3 OVERVIEW 32
- 1.4 CURRENCY AND PRICING 34
- 1.5 LIMITATIONS 34
- 1.6 MARKETS COVERED 34
2 MARKET SEGMENTATION 37
- 2.1 MARKETS COVERED 37
- 2.2 GEOGRAPHICAL SCOPE 38
- 2.3 YEARS CONSIDERED FOR THE STUDY 39
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 40
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 43
- 2.6 MULTIVARIATE MODELLING 44
- 2.7 MARKET APPLICATION COVERAGE GRID 45
- 2.8 PRODUCT LIFELINE CURVE 46
- 2.9 DBMR MARKET POSITION GRID 47
- 2.10 VENDOR SHARE ANALYSIS 48
- 2.11 SECONDARY SOURCES 49
- 2.12 ASSUMPTIONS 49
3 EXECUTIVE SUMMARY 50
4 PREMIUM INSIGHTS 52
- 4.1 PESTEL ANALYSIS 55
- 4.2 PORTER FIVE FORCES 56
- 4.3 PATENT ANALYSIS 57
- 4.4 PATIENT FLOW DIAGRAM 58
- 4.5 KEY PRICING STRATEGIES 59
- 4.6 FUTURE THERAPIES 60
- 4.7 KEY PATIENT ENROLLMENT STRATEGIES 61
5 PIPELINE ANALYSIS 62
6 EPIDEMIOLOGY 63
7 INDUSTRY INSIGHTS 64
8 GLOBAL PEMPHIGUS VULGARIS MARKET: REGULATIONS 65
9 MARKET OVERVIEW 68
- 9.1 DRIVERS 70
- 9.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS 70
- 9.1.2 GROWING SUPPORT OF NGOS FOR THE AFFECTED PATIENTS 70
- 9.1.3 AWARENESS REGARDING THE DISEASE 71
- 9.2 RESTRAINTS 71
- 9.2.1 STRICT REGULATORY GUIDELINES 71
- 9.2.2 HIGH TREATMENT COSTS 71
- 9.3 OPPORTUNITIES 72
- 9.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 72
- 9.3.2 INCREASING HEALTHCARE FACILITIES 72
- 9.3.3 DIGITAL HEALTH TECHNOLOGIES FOR TREATMENT MANAGEMENT 73
- 9.4 CHALLENGES 73
- 9.4.1 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS 73
- 9.4.2 REIMBURSEMENT AND COVERAGE POLICIES 74
10 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT 75
- 10.1 OVERVIEW 76
- 10.2 TREATMENT 79
- 10.2.1 MEDICATIONS, BY TYPE 79
- 10.2.1.1 CORTICOSTEROIDS 80
- 10.2.1.2 STEROID- SPARING IMMUNOSUPPRESSANT DRUGS 80
- 10.2.1.2.1 AZATHIOPRINE 81
- 10.2.1.2.2 MYCOPHENALATE MOFETIL 81
- 10.2.1.2.3 METHOTREXATE 81
- 10.2.1.2.4 CYCLOPHOSPHAMIDE 81
- 10.2.1.2.5 MIZORIBINE 81
- 10.2.1.2.6 OTHERS 81
- 10.2.1.3 ANTI- INFLAMMATORY AGENTS 81
- 10.2.1.3.1 DIAMINODYPHENYL SULFONE 82
- 10.2.1.3.2 TETRACYCLINE 82
- 10.2.1.3.3 OTHERS 82
- 10.2.1.4 BIOLOGICS 82
- 10.2.1.5 INTRAVENOUS IMMUNOGLOBULIN 82
- 10.2.1.6 ANTIBIOTICS 82
- 10.2.1.7 ANTIFUNGALS 82
- 10.2.1.8 ANTIVIRALS 82
- 10.2.1.9 OTHER MEDICATIONS 82
- 10.2.2 MEDICATIONS, BY ROUTE OF ADMINISTRATION 82
- 10.2.2.1 ORAL 83
- 10.2.2.2 TOPICAL 83
- 10.2.2.3 PARENTERAL 83
- 10.2.2.4 OTHERS 83
- 10.2.3 MEDICATIONS, BY DRUG TYPE 83
- 10.2.3.1 GENERIC 84
- 10.2.3.2 BRANDED 84
- 10.3 DIAGNOSIS 84
- 10.3.1 SKIN BIOPSY 85
- 10.3.2 BLOOD TEST 85
- 10.3.3 ENDOSCOPY 85
11 GLOBAL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE 86
- 11.1 OVERVIEW 87
- 11.2 ADULTS 90
- 11.3 GERIATRIC 91
- 11.4 PEDIATRIC 92
12 GLOBAL PEMPHIGUS VULGARIS MARKET, BY END USER 93
- 12.1 OVERVIEW 94
- 12.2 HOSPITALS 97
- 12.3 SPECIALTY CLINICS 97
- 12.4 RESEARCH INSTITUTES 98
- 12.5 OTHERS 99
13 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL 100
- 13.1 OVERVIEW 101
- 13.2 HOSPITALS PHARMACY 104
- 13.3 RETAIL PHARMACY 104
- 13.4 ONLINE PHARMACY 105
14 GLOBAL PEMPHIGUS VULGARIS MARKET, BY REGION 106
- 14.1 OVERVIEW 107
- 14.2 NORTH AMERICA 112
- 14.2.1 U.S. 120
- 14.2.2 CANADA 124
- 14.2.3 MEXICO 128
- 14.3 EUROPE 132
- 14.3.1 GERMANY 141
- 14.3.2 U.K. 145
- 14.3.3 FRANCE 149
- 14.3.4 ITALY 153
- 14.3.5 SPAIN 157
- 14.3.6 SWITZERLAND 161
- 14.3.7 TURKEY 165
- 14.3.8 RUSSIA 169
- 14.3.9 BELGIUM 173
- 14.3.10 NETHERLANDS 177
- 14.3.11 REST OF EUROPE 180
- 14.4 ASIA-PACIFIC 181
- 14.4.1 CHINA 190
- 14.4.2 INDIA 194
- 14.4.3 SOUTH KOREA 198
- 14.4.4 MALAYSIA 202
- 14.4.5 JAPAN 206
- 14.4.6 AUSTRALIA 210
- 14.4.7 SINGAPORE 214
- 14.4.8 THAILAND 218
- 14.4.9 INDONESIA 222
- 14.4.10 PHILIPPINES 226
- 14.4.11 REST OF ASIA-PACIFIC 229
- 14.5 SOUTH AMERICA 230
- 14.5.1 BRAZIL 238
- 14.5.2 ARGENTINA 242
- 14.5.3 REST OF SOUTH AMERICA 246
- 14.6 MIDDLE EAST AND AFRICA 247
- 14.6.1 SAUDI ARABIA 255
- 14.6.2 EGYPT 259
- 14.6.3 U.A.E. 263
- 14.6.4 SOUTH AFRICA 267
- 14.6.5 ISRAEL 271
- 14.6.6 REST OF MIDDLE EAST AND AFRICA 274
15 GLOBAL PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE 275
- 15.1 COMPANY SHARE ANALYSIS: GLOBAL 275
- 15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 276
- 15.3 COMPANY SHARE ANALYSIS: EUROPE 277
- 15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 278
16 SWOT ANALYSIS 279
17 COMPANY PROFILE 280
- 17.1 ABBVIE INC. 280
- 17.1.1 COMPANY SNAPSHOT 280
- 17.1.2 REVENUE ANALYSIS 280
- 17.1.3 COMPANY SHARE ANALYSIS 281
- 17.1.4 PRODUCT PORTFOLIO 281
- 17.1.5 RECENT DEVELOPMENTS 282
- 17.2 MERCK & CO., INC., 283
- 17.2.1 COMPANY SNAPSHOT 283
- 17.2.2 REVENUE ANALYSIS 283
- 17.2.3 COMPANY SHARE ANALYSIS 284
- 17.2.4 PRODUCT PORTFOLIO 284
- 17.2.5 RECENT DEVELOPMENT 284
- 17.3 SANOFI 285
- 17.3.1 COMPANY SNAPSHOT 285
- 17.3.2 REVENUE ANALYSIS 285
- 17.3.3 COMPANY SHARE ANALYSIS 286
- 17.3.4 PRODUCT PORTFOLIO 286
- 17.3.5 RECENT DEVELOPMENT 286
- 17.4 REGENERON PHARMACEUTICALS INC. 287
- 17.4.1 COMPANY SNAPSHOT 287
- 17.4.2 REVENUE ANALYSIS 287
- 17.4.3 COMPANY SHARE ANALYSIS 288
- 17.4.4 PRODUCT PORTFOLIO 288
- 17.4.5 RECENT DEVELOPMENT 288
- 17.5 NOVARTIS AG 289
- 17.5.1 COMPANY SNAPSHOT 289
- 17.5.2 REVENUE ANALYSIS 289
- 17.5.3 COMPANY SHARE ANALYSIS 290
- 17.5.4 PRODUCT PORTFOLIO 290
- 17.5.5 RECENT DEVELOPMENT 290
- 17.6 AMGEN INC. 291
- 17.6.1 COMPANY SNAPSHOT 291
- 17.6.2 REVENUE ANALYSIS 291
- 17.6.3 PRODUCT PORTFOLIO 292
- 17.6.4 RECENT DEVELOPMENTS 292
- 17.7 ASTRAZENECA 293
- 17.7.1 COMPANY SNAPSHOT 293
- 17.7.2 REVENUE ANALYSIS 293
- 17.7.3 COMPANY SHARE ANALYSIS 294
- 17.7.4 PRODUCT PORTFOLIO 294
- 17.7.5 RECENT DEVELOPMENTS 295
- 17.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 296
- 17.8.1 COMPANY SNAPSHOT 296
- 17.8.2 REVENUE ANALYSIS 296
- 17.8.3 PRODUCT PORTFOLIO 297
- 17.8.4 RECENT DEVELOPMENT 297
- 17.9 CELLTRION HEALTHCARE CO., LTD 298
- 17.9.1 COMPANY SNAPSHOT 298
- 17.9.2 REVENUE ANALYSIS 298
- 17.9.3 PRODUCT PORTFOLIO 299
- 17.9.4 RECENT DEVELOPMENTS 299
- 17.10 F. HOFFMANN- LA ROCHE LTD. 300
- 17.10.1 COMPANY SNAPSHOT 300
- 17.10.2 REVENUE ANALYSIS 300
- 17.10.3 PRODUCT PORTFOLIO 301
- 17.10.4 RECENT DEVELOPMENT 301
- 17.11 FRESENIUS KABI AG 302
- 17.11.1 COMPANY SNAPSHOT 302
- 17.11.2 REVENUE ANALYSIS 302
- 17.11.3 PRODUCT PORTFOLIO 303
- 17.11.4 RECENT DEVELOPMENT 303
- 17.12 GSK PLC 304
- 17.12.1 COMPANY SNAPSHOT 304
- 17.12.2 REVENUE ANALYSIS 304
- 17.12.3 PRODUCT PORTFOLIO 305
- 17.12.4 RECENT DEVELOPMENT 305
- 17.13 JOHNSON & JOHNSON SERVICES, INC. 306
- 17.13.1 COMPANY SNAPSHOT 306
- 17.13.2 REVENUE ANALYSIS 306
- 17.13.3 COMPANY SHARE ANALYSIS 307
- 17.13.4 PRODUCT PORTFOLIO 307
- 17.13.5 RECENT DEVELOPMENT 307
- 17.14 LILLY 308
- 17.14.1 COMPANY SNAPSHOT 308
- 17.14.2 REVENUE ANALYSIS 308
- 17.14.3 PRODUCT PORTFOLIO 309
- 17.14.4 RECENT DEVELOPMENT 309
- 17.15 PFIZER INC. 310
- 17.15.1 COMPANY SNAPSHOT 310
- 17.15.2 REVENUE ANALYSIS 310
- 17.15.3 PRODUCT PORTFOLIO 311
- 17.15.4 RECENT DEVELOPMENT 311
- 17.16 RAKSHIT DRUGS PVT. LTD 312
- 17.16.1 COMPANY SNAPSHOT 312
- 17.16.2 PRODUCT PORTFOLIO 312
- 17.16.3 RECENT DEVELOPMENT 312
- 17.17 TEVA PHARMACEUTICAL INDUSTRIES LTD 313
- 17.17.1 COMPANY SNAPSHOT 313
- 17.17.2 REVENUE ANALYSIS 313
- 17.17.3 PRODUCT PORTFOLIO 314
- 17.17.4 RECENT DEVELOPMENT 314
- 17.18 ZYDUS GROUP 315
- 17.18.1 COMPANY SNAPSHOT 315
- 17.18.2 REVENUE ANALYSIS 315
- 17.18.3 PRODUCT PORTFOLIO 316
- 17.18.4 RECENT DEVELOPMENT 316
18 QUESTIONNAIRE 317
19 RELATED REPORTS 319